OCA
AUTL

OpenArc Corporate Advisory’s Autolus Therapeutics AUTL Stock Holding History

OpenArc Corporate Advisory’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-84,850
Closed -$169K – 720
2025
Q4 		$169K Buy
+84,850
New +$130K ﹤0.01% 628

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

OpenArc Corporate Advisory's AUTL Position: Q1 2026 in Review

OpenArc Corporate Advisory sold out of Autolus Therapeutics (AUTL) in Q1 2026, closing a stake of 84,850 shares — an estimated $169K sold.

OpenArc Corporate Advisory first reported a position in AUTL in Q4 2025 and held it in 1 quarter. The position peaked at $169K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • OpenArc Corporate Advisory reported no remaining Autolus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OpenArc Corporate Advisory sold 84,850 Autolus Therapeutics shares in Q1 2026, an estimated $169K.
  • OpenArc Corporate Advisory first reported a position in Autolus Therapeutics in Q4 2025 and held it in 1 quarter.
  • OpenArc Corporate Advisory's Autolus Therapeutics position peaked at $169K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q1 2026, filed 11 May 2026.